Lawsuit filed for Investors who lost money with shares of Tempus AI, Inc. (NASDAQ: TEM)

An investor, who purchased shares of Tempus AI, Inc. (NASDAQ: TEM), filed a lawsuit over alleged violations of Federal Securities Laws by Tempus AI, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and for certain investors are short and strict deadlines running. Deadline: August 12, 2025. NASDAQ: TEM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Chicago, IL based Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. Tempus AI, Inc. (NASDAQ: TEM) reported that its annual Total Revenue rose from $531.82 million in 2023 to $693,39 million in 2024, and that its Net Loss increased from $214.11 million in 2023 to $705.8 million in 2024.

On May 28, 2025, Spruce Point Capital Management, LLC issued a research report on Tempus AI, Inc. (NASDAQ: TEM) that raised numerous red flags over Tempus AI's' management, operations and financial reporting (the "Spruce Point Report"). The Spruce Point Report scrutinized Tempus AI, Inc. on an array of issues, including: (1) Tempus AI, Inc. CEO Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus AI's actual AI capabilities are over overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance revision reveals weakness in core operations.

Shares of Tempus AI, Inc. (NASDAQ: TEM) declined from $71.97 per share on May 14, 2025, to $52.55 per share on May 28, 2025.

According to the complaint the plaintiff alleges on behalf of purchasers of Tempus AI, Inc. (NASDAQ: TEM) common shares between August 6, 2024 and May 27, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2024 and May 27, 2025, Tempus AI, Inc. branded itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements, that the Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding, that Tempus AI, Inc. often reported on its relationship with long-term customer AstraZeneca as an example, that importantly between August 6, 2024 and May 27, 2025, Tempus AI, Inc. announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI, that the Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market, that Tempus AI, Inc. additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired between August 6, 2024 and May 27, 2025, and that Tempus AI, Inc. claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.

Those who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.